| Literature DB >> 31992566 |
Ashleigh R Poh1, Amy R Dwyer2, Moritz F Eissmann1, Ashwini L Chand1, David Baloyan1, Louis Boon3, Michael W Murrey4, Lachlan Whitehead5, Megan O'Brien1, Clifford A Lowell6, Tracy L Putoczki5, Fiona J Pixley4, Robert J J O'Donoghue7, Matthias Ernst8.
Abstract
Persistent activation of the latent transcription factor STAT3 is observed in gastric tumor epithelial and immune cells and is associated with a poor patient prognosis. Although targeting STAT3-activating upstream kinases offers therapeutically viable targets with limited specificity, direct inhibition of STAT3 remains challenging. Here we provide functional evidence that myeloid-specific hematopoietic cell kinase (HCK) activity can drive STAT3-dependent epithelial tumor growth in mice and is associated with alternative macrophage activation alongside matrix remodeling and tumor cell invasion. Accordingly, genetic reduction of HCK expression in bone marrow-derived cells or systemic pharmacologic inhibition of HCK activity suppresses alternative macrophage polarization and epithelial STAT3 activation, and impairs tumor growth. These data validate HCK as a molecular target for the treatment of human solid tumors harboring excessive STAT3 activity. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31992566 PMCID: PMC8064588 DOI: 10.1158/2326-6066.CIR-19-0623
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151